A strain of bacteria listed as Mycobacterium phlei ATCC 356 (hereafter referred to as strain 356) was obtained from the American Type Culture Collection, Rockville, Md., and has been used in these laboratories for several years in the study of fatty acid biosynthesis (4 and references therein). It was assumed that this strain was representative of the species M. phlei.
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Since it was knowh that 6-methylsalicylic acid (6-MSA) is synthesized via the polyketide pathway and excreted into the growth medium by M. phlei ATCC 354 and M. phZei ATCC 10142 (3), the study of 6-MSA biosynthesis in strain 356 was undertaken. It was subsequently found that crude extracts of this organism failed t o synthesize 6-MSA from acetyl-coenzyme A and malonyl-coenzyme A in the presence of reduced nicotinamide adenine dinucleotide phosphate. In contrast, crude extracts of both M. phZei ATCC 354 and M. phlei ATCC 10142 were found to exhibit 6-MSA synthetase activity under the same conditions. Mycobactin P, which is made exclusively by strains of M. phlei, is known to contain 6-MSA (7). It might be expected that mycobacterial species which do not produce a mycobactin containing 6-MSA would not synthesize 6-MSA. Indeed, Mycobacterium srnegmatis is known t o produce mycobactin S, which contains salicylic acid instead of 6-MSA (7), and extracts of M. smegmatis show salicylic acid synthetic capacity, whereas extracts of M. phlei are completely inactive in this respect (4, 6). The absence of 6-MSA synthetic ability in a mycobacterial strain presumed t o be M. phlei seemed curious. 
